Research Tracker›Biomarker Atlas›Long COVID›Complement C3a / C5a

Complement C3a / C5a in Long COVID

Complement C3a / C5a, also described as Anaphylatoxins, belongs to the immune group of Long COVID (PASC, Post-Acute Sequelae of COVID-19) markers and is reported to be raised relative to healthy controls. Symptom domains tied to this marker in the source include complement activation. The finding is drawn from Baalbaki et al. 2025; it describes group-level differences, not a threshold that classifies an individual.

↑ ElevatedImmune

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryImmune
Also described asAnaphylatoxins
Compared againstHC (healthy controls)
Associated symptomsComplement activation
Test typeBlood test (serum / plasma / whole blood)
SourceBaalbaki et al. 2025 — doi:10.1111/all.16526
Condition atlasLong COVID Biomarker Atlas

Related Immune markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is Complement C3a / C5a high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher Complement C3a / C5a in Long COVID than in healthy controls. Source: Baalbaki et al. 2025.

What symptoms is Complement C3a / C5a associated with in Long COVID?

The cited literature associates this marker with Complement activation. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Complement C3a / C5a?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Complement C3a / C5a result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. Complement C3a / C5a findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Complement C3a / C5a in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/complement-c3a-c5a.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.